NICE Opposes Zeposia Being Added to RRMS Therapies in UK’s Health Service

NICE Opposes Zeposia Being Added to RRMS Therapies in UK’s Health Service

283976

NICE Opposes Zeposia Being Added to RRMS Therapies in UK’s Health Service

The National Institute for Health and Care Excellence (NICE) does not recommend Zeposia (ozanimod) be available at low or no cost through the National Health Service (NHS) to treat adults with active relapsing-remitting multiple sclerosis (RRMS) living in England and Wales. In a recent draft recommendation, NICE stated that data from two clinical trials — the Phase 3 SUNBEAM (NCT02294058) and the Phase 3 portion of RADIANCE (NCT02047734) —  showed Zeposia was superior to Avonex (interferon beta-1a, by Biogen)…

You must be logged in to read/download the full post.